Q-omics provides the consensus-scored KCTD3 profile across patient tissues and cancer cell-line models. KCTD3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, KCTD3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, KCTD3 RNA expression shows 20,469 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where KCTD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCTD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCTD3 survival associations across molecular data types. KCTD3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCTD3 RNA expression–survival associations across cancer types. High KCTD3 expression shows unfavorable associations in UVM, LUAD, ACC, KIRP and BLCA, but favorable associations in BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for KCTD3 RNA expression.
This table summarizes KCTD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KCTD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCTD3 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, KIRP, LIHC and BRCA. The KIRC box plot shows higher KCTD3 RNA expression in tumor versus normal tissue (log2 FC = +1.035, t-test p < 0.001).
This table shows molecular features associated with KCTD3 in patient tissues and cancer cell lines. In patient samples, KCTD3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCTD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
